Top Markets
Coin of the day
Climb Bio, Inc. Climb Bio, Inc.

Climb Bio, Inc.

CLYM
Classement en actions #10440
Climb Bio, Inc. is a biopharmaceutical firm dedicated to crafting therapeutic... Climb Bio, Inc. is a biopharmaceutical firm dedicated to crafting therapeutic solutions for inflammatory diseases driven by autoimmune responses. Its primary investigational asset is budoprutug, an anti-CD19 monoclonal antibody. This treatment is being advanced for a range of autoimmune conditions, including systemic lupus erythematosus, lupus nephritis, immune thrombocytopenia, and membranous nephropathy. The entity, established in 2018, officially rebranded as Climb Bio, Inc. in October 2024, having previously operated under the name Eliem Therapeutics, Inc. Its corporate headquarters are situated in Wilmington, Delaware.
Prix de l'action
$14.66
Dernière synchronisation: 2026-08-28
Capitalisation boursière
$839.37M
Changement (1 jour)
-2.67%
Changement (1 an)
557.32%
Pays
US
Échange Climb Bio, Inc. (CLYM)

Catégorie

Historique du rendement du dividende pour Climb Bio, Inc. (CLYM)
Le rendement du dividende (TTM) de Climb Bio, Inc. (symbole boursier : CLYM) au 2026 est : 0
Rendement moyen du dividende sur les 5 dernières années : 0.00%
Historique du rendement du dividende de Climb Bio, Inc. (CLYM) de 2026 à 2026
Rendement du dividende à la fin de chaque année (TTM)
Année Rendement du dividende Changez
Pas assez de données pour les dates fournies.
Rendements du dividende (TTM) pour des entreprises similaires ou concurrentes
Entreprise Rendement du dividende Pays
0.00%
US
0.00%
NL
3.12%
AU
0.00%
US
0.00%
CH